1 / 50

M & M “it’s probably in your head”

M & M “it’s probably in your head”. Kommerien Daling 2-14-08. CASE. 11/19/07: Acute visit. 30 yo WM, C/O tingling Rt leg on 11/14. Resolved while driving to FL for wedding. Next day tingling Lt leg, scrotum, Rt arm, Lt buttock. CHART REVIEW.

elkan
Download Presentation

M & M “it’s probably in your head”

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. M & M“it’s probably in your head” Kommerien Daling 2-14-08

  2. CASE • 11/19/07: Acute visit. 30 yo WM, C/O tingling Rt leg on 11/14. Resolved while driving to FL for wedding. Next day tingling Lt leg, scrotum, Rt arm, Lt buttock.

  3. CHART REVIEW • 5/05: new patient visit. Depression. Rhinitis. Lexapro. Allegra. • 9/05: ED. D/C Lexapro, start Wellbutrin • 12/05: CP. Panick attacks. Lexapro. • 9/13/06: Anxiety. Mass on testicle. Acute prostatis. Get Gc/chlam. Doxy. Anxiety. Lexapro • 9/15/06 Letter to patient: Gc/Chlam neg. RTC if sx continue. • 10/16/06: Reschedule. Pt canceled. • 5/07: HA. Migraine vs tension.

  4. CHART REVIEW • 6/07: 1) Allergic rhinitis 2) Anxiety 3) Chronic prostatis, controlled. • 9/07: stomach pain, N/V. AGE. Viral • 10/07: Rt arm pain. Tendinitis.

  5. CASE • 11/19/07: Acute visit. • 30 yo WM, H/O anxiety, c/o tingling Rt leg on 11/14. Resolved while driving to FL for wedding. Next day tingling Lt leg, scrotum, Rt arm, Lt buttock. • O/ NEU wnl. Rt testis wnl. Lt testis nodule 1 cm • A/P 1) Paraesthesias. 2) L test. nodule: epididymal cyst? -> US. 3) Anxiety

  6. CHART REVIEW • 9/13/06 S/ Anxiety. Mass on testicle. Increasing low grade pain after ejaculation. O/ Lt testicle w/ mass, prominent epididymis, minimal pain. Some TTP of prostate, but not exquisite. UA-ve. A/P 1) Acute prostatitis, Gc/chlam obtained. Rx Doxy. 2) Anxiety. Restart Lexapro (quit in 3/06).

  7. CASE • 12/12/07 US: area of heterogenous decreased echogenicity with increased Doppler signal in postero-inferior testicle, very suspicious for testicular carcinoma. 2.1 x 1.4 x 1.5 cm

  8. CASE • 12/13/07 referral CT abd/pelvis, CXR, Referral to Urology, 1/2/08 • 12/17 Firm mass Lt testicle inferiorly, no hernias. Appointments confirmed with patient. Labs: LDH, AFP, ß-HCG. B-12 borderline low -> PO vit B12.

  9. CASE • 1/2/08. Urology note: Pt noticed mass/fullness Lt testicle for 15 months, when initially seen not palpable, was told: “it’s probably in your head” • Sperm banking & testicular prosthesis discussed with patient • 1/10/08 Lt ing radical orchiectomy. Seminoma.

  10. Epidemiology of TC • 2007: New Cases 7920, Deaths 380 • 1% of all solid tumors in males • Most common malignancy in 15-34yo M (25% of cancer cases, 5% of cancer deaths) • Peak incidence 25-35yo • US life time risk 3-4/1000 • 3.7/100.000/yr in whites, 0.9/100.000/yr in blacks, 8.2/100.000/yr in Denmark • Increasing trends 1960s-80s in whites, 1990s in blacks

  11. Testicular cancer

  12. Risk factors for testis cancer • Cryptorchidism (testicularmaldescent)—2–10 fold increase in risk • Carcinomain situ (intratubular germ cell neoplasia -> 50% cancer in 5 yrs) • H/Otestis cancer or extragonadal germ cell tumour. 2-3% • Family history—relativerisk 8–10 fold in brothers, 4- fold in sons of affectedman. (2% absolute risk) • HIV infection—increased risk of seminoma (x21?) • Caucasian. Danes • Testicular trauma • Infertility/subfertility 2-3x risk later in life

  13. Risk factors for testis cancer • No proven association with: • Intra-uterine estrogen/androgen exposure, DES • Tight underwear • Sedentary lifestyle • Early exposure to viruses • Vasectomy

  14. Genetics Duplication oramplification of the short arm of chromosome 12 (12p)is seenin almost all cases of testis cancer, implying that a key geneis present in this area.

  15. Presentation • Painless mass • Dull ache or heavy sensation in lower abdomen/perianal/scrotum 30-40% • Acute pain 10% • Gynaecomastia 10% • Diffuse swelling/hydrocele • Infertility • Hematospermia

  16. Clinical manifestations of testis cancer from metastaticdisease*Systemic symptoms: anorexia, malaise, weight loss * Coughor shortness of breath due to pulmonary metastases * Neck massdue to lymph node metastases * Lower back pain from bulky retroperitonealdisease * Lower extremity swelling due to iliac or caval obstructionorthrombosis (unilateral or bilateral) * Nausea, vomiting orgastrointestinal haemorrhage fromretroduodenal metastases * Bonypain* Central or peripheral nervous system symptoms from cerebral,spinal cord or peripheral nerve root involvement

  17. Testicular mass/pain: DDx • Testiculartorsion: acute, severe pain is a common presenting feature • Epididymitis/epididymo-orchitis:associated with fever, pain not as acute • Testicular cancer • Hydrocoele • Varicocoele • Hernia • Hematoma, trauma • Spermatocele • Vasculitis: Polyarteritis nodosa, HSP • Acute idiopathic scrotal edema • Syphilitic gumma

  18. Testis Cancer ? Evaluation • PE: abd, scrotal exam(testis, epididymis, cord, skin), inguinal region, breasts, rectal, supra clavicular lymphnodes • UA • Scrotal US, color Doppler

  19. Chronic testicular pain

  20. Acute scrotal pain

  21. Scrotal US findings • Sufficient for dx of TC in majority • Conditions which may mimic neoplasia: inflammation, hematoma, infarct, fibrosis, tubular ectasia • Small superficial calc. -> no futher eval • Microcalcifications: possible CIS • MRI if US inconclusive, NPV 100%, PPV 71%

  22. Evaluation for staging • Tumor markers AFP, HCG, LDH • CXR, CT abd/pelvis, CT or MRI brain PRN

  23. Testicular cancer • 95% GCT, 5% others (Leydig, lymphoma) • Sx prior to Dx 17-87 wks • Tumor doubling 10-30 days

  24. LDH: elevated in 50%, not specific to type, proportionate to tumor size

  25. Staging of TC • Stage I - Stage I testicular cancer is limited to the testis/epididymis/scrotum/spermatic cord. • Stage II - Stage II testicular cancer involves the testis and the retroperitoneal or para-aortic lymph nodes usually in the region of the kidney. • Stage III - Stage III implies spread beyond the retroperitoneal nodes based on physical examination, x-rays, and/or blood tests. Stage III is subdivided into nonbulky stage III versus bulky stage III.

  26. Primary tumor (T) - The extent of primary tumor is classified after radical orchiectomy. • pTX: Primary tumor cannot be assessed (if no radical orchiectomy has been performed, TX is used.) • pT0: No evidence of primary tumor (e.g., histologic scar in testis) • pTis: Intratubular germ cell neoplasia (carcinoma in situ) • pT1: Tumor limited to testis and epididymis without lymphatic/vascular invasion • pT2: Tumor limited to testis and epididymis with vascular/lymphatic invasion, or tumor extending through the tunica albuginea with involvement of the tunica vaginalis • pT3: Tumor invades the spermatic cord with or without vascular/lymphatic invasion • pT4: Tumor invades the scrotum with or without vascular/lymphatic invasion

  27. Regional lymph nodes (N) • NX: Regional lymph nodes cannot be assessed • N0: No regional lymph node metastasis • N1: Metastasis in a single lymph node, 2 cm or less in greatest dimension • N2: Metastasis in a single lymph node, more than 2 cm but not more than 5 cm in greatest dimension; or multiple lymph nodes, none more than 5 cm in greatest dimension • N3: Metastasis in a lymph node more than 5 cm in greatest dimension

  28. Distant metastasis (M) • MX: Presence of distant metastasis cannot be assessed • M0: No distant metastasis • M1: Distant metastasis • M1a: Non-regional nodal or pulmonary metastasis • M1b: Distant metastasis other than to non-regional nodes and lungs

  29. Serum tumor markers (S) • SX: Tumor marker studies not available or not performed • S0: Tumor marker levels within normal limits • S1: LDH < 1.5 X Normal and HCG (mIu/ml) < 5000 and AFP (ug/ml) < 1000 • S2: LDH 1.5-10 X Normal or HCG (mIu/ml) 5000-50,000 or AFP (ug/ml) 1000-10,000 • S3: LDH > 10 X Normal or HCG (mIu/ml) > 50,000 or AFP (ug/ml) > 10,000

  30. Stage 0 pTis, N0, M0, S0 Stage I pT1-4, N0, M0, SX Stage IA pT1, N0, M0, S0 Stage IB pT2, N0, M0, S0pT3, N0, M0, S0pT4, N0, M0, S0 Stage IS Any pT/Tx, N0, M0, S1-3 Stage II Any pT/Tx, N1-3, M0, SX Stage IIA Any pT/Tx, N1, M0, S0Any pT/Tx, N1, M0, S1 Stage IIB Any pT/Tx, N2, M0, S0Any pT/Tx, N2, M0, S1 Stage IIC Any pT/Tx, N3, M0, S0Any pT/Tx, N3, M0, S1 Stage III Any pT/Tx, Any N, M1, SX Stage IIIA Any pT/Tx, Any N, M1a, S0Any pT/Tx, Any N, M1a, S1 Stage IIIB Any pT/Tx, N1-3, M0, S2Any pT/Tx, Any N, M1a, S2 Stage IIIC Any pT/Tx, N1-3, M0, S3Any pT/Tx, Any N, M1a, S3Any pT/Tx, Any N, M1b, Any S

  31. Prognosis • 1963 5-yr survival 63% • Current 5yr survival > 95% • Stage 1 98% • Stage 2 early: > 90% • Stage 2 late: similar to stage 3 • Stage 3: 90/75/50%

  32. Treatment stage 1 • Seminomas : surveillance, radiation,chemotherapy • Nonseminomas: surveillance, retroperitoneal lymphnode resection, chemotherapy 70-80% cured with orchiectomy alone. disease-specific survival in the range of 98% to100% regardless of which approach

  33. Treatment stage 2 • small-volumeretroperitoneal metastases and tumormarker levels wnl: RPLND for NS RXT for seminoma • larger-volume diseaseor elevated serum tumor markers or both: chemotherapy

  34. Treatment stage 3 • good-risk tumors: 9 wk BEP or 12wk EP • intermediate-risk and poor-risk tumors: 12 wk BEP. • Relapseafter first-line chemo can be cured 2n-line therapy 25% to 45% of the time

  35. Early side effects Chemo • pancytopenia, fatigue, nausea, vomiting, hearingloss, peripheral neuropathy, and reducedrenal function,loss of work time Radiation • Nausea, fatigue, loss of work

  36. Long term side effects of adjuvant treatment • In/subfertility, hypogonadism • 2ndary tumors • Increased cardiovascular events • Increased risk of metabolic syndrome • Pulmonary fibrosis • Pulmonary death in 0.2% - 2% (4 cycles) • Death from infectious diseases • peripheral neuropathy, hearing loss, • tinnitus, Raynaud phenomenon • Renal insufficiency

  37. Testicular Cancer. Follow Up • Frequency, duration & testing depends on stage, type, and treatment

  38. Clinical Stage I Seminoma - Treated with Adjuvant Radiation(Nichols Protocol) • Year 1: Tumor Markers and Chest X-ray done every 2 months • Year 2: Tumor Markers and Chest X-ray done every 4 months • Years 3-5: Tumor Markers and Chest X-ray done every 6 months • After Year 5: Tumor Markers and Chest X-ray done once a year

  39. Clinical Stage I Seminoma - Treated with Surveillance only (Nichols Protocol) • Year 1: Tumor Markers and Chest X-ray done every 2 monthsAbdominal CT scan done every 3 months • Year 2: Tumor Markers and Chest X-ray done every 2 monthsAbdominal CT scan done every 4 months • Years 3-5: Tumor Markers and Chest X-ray done every 6 monthsAbdominal CT scan done every 6 months • After Year 5: Tumor Markers and Chest X-ray done once a year

  40. CIS (intra tubular GCT) Suspect and consider biopsy in: • Contralateral testis of TC patient • Intersex patients (Klinefelter) • Selected cases with in/subfertility: atrophic testis & microcalcifications on US • Assumed extra gonadal GCT

  41. CIS • Dx: surgical biopsy 3x3 mm, 30-40 tubules is representative • Eval: staging with CXR, CT, markers • Treatment Unilateral: orchiectomy Bilateral or contralateral: local RXT & F/U bx. • Consider semen cryopreservation • Check testosteron levels, replacement PRN

  42. Screening The USPSTF recommends against routine screening for testicular cancer in asymptomatic adolescent and adult males. No evidence that screening with clinical examination or testicular self-examination is effective in reducing mortality from testicular cancer. Even in the absence of screening, the current treatment interventions provide very favorable health outcomes. Given the low prevalence of testicular cancer, limited accuracy of screening tests, and no evidence for the incremental benefits of screening, the USPSTF concluded that the harms of screening exceed any potential benefits. • USPSTF recommendation: D

  43. NCI / PDQ (physician data query) • Benefits Based on fair evidence, screening for testicular cancer would not result in an appreciable decrease in mortality, in part because therapy at each stage is so effective. • Harms Based on fair evidence, screening for testicular cancer would result in unnecessary diagnostic procedures with attendant morbidity. • Direction and Magnitude of Effect: Fair evidence of no reduction in mortality; good evidence for rare but serious harms.

  44. Drawing 1. Cup your scrotum with one hand to see if it feels normal. Drawing 2. Feel for any lumps in or on the side of the testicle. Drawing 3. Feel along the epididymis for swelling.

  45. Returning to CASE • Stage 1 seminoma • Uncomplicated recovery from surgery • Uro referred to radio-onc • Has chosen for adjuvant RTX • Patient still to decide on sperm banking • Operation report and pathology report do not mention biopsy of the contra-lateral testicle

  46. Factors leading to delayed Dx • “Atypical” presentation with pain • No US obtained at first presentation • Patient canceled F/U appointment • Subsequently no continuity of care • Difficult-to-read office notes • Prior diagnosis of anxiety ? • Embarrasment w/regard to scrotal exam ?

  47. Recommendations for practice • Low-to-no threshold for scrotal US • Recognize atypical presentations • Continuity of care • Legible hand writing: notes and signature • Contactibility of physician and patient • Be aware of embarrasment

More Related